Prediction of CCND1 amplification using plasma DNA as a prognostic marker in oesophageal squamous cell carcinoma

BACKGROUND: We aimed to develop a new biomarker to predict cyclin D1 (CCND1) status using plasma DNA in oesophageal squamous cell carcinoma (ESCC) patients. METHODS: We evaluated the ratio of the CCND1 (11q13) dosage to the dopamine receptor D2 (DRD2; 11q22-23) dosage (C/D ratio) as CCND1 copy numbe...

Descripción completa

Detalles Bibliográficos
Autores principales: Takeshita, H, Ichikawa, D, Komatsu, S, Tsujiura, M, Kosuga, T, Deguchi, K, Konishi, H, Morimura, R, Shiozaki, A, Fujiwara, H, Okamoto, K, Otsuji, E
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2010
Materias:
Molecular Diagnostics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2865765/
https://www.ncbi.nlm.nih.gov/pubmed/20389301
http://dx.doi.org/10.1038/sj.bjc.6605657
_version_ 1782180867040346112
author Takeshita, H
Ichikawa, D
Komatsu, S
Tsujiura, M
Kosuga, T
Deguchi, K
Konishi, H
Morimura, R
Shiozaki, A
Fujiwara, H
Okamoto, K
Otsuji, E
author_facet Takeshita, H
Ichikawa, D
Komatsu, S
Tsujiura, M
Kosuga, T
Deguchi, K
Konishi, H
Morimura, R
Shiozaki, A
Fujiwara, H
Okamoto, K
Otsuji, E
author_sort Takeshita, H
collection PubMed
description BACKGROUND: We aimed to develop a new biomarker to predict cyclin D1 (CCND1) status using plasma DNA in oesophageal squamous cell carcinoma (ESCC) patients. METHODS: We evaluated the ratio of the CCND1 (11q13) dosage to the dopamine receptor D2 (DRD2; 11q22-23) dosage (C/D ratio) as CCND1 copy number. This study was divided into three steps: (1) Determination of a cutoff value for the C/D ratio in test scale; (2) Comparison of the C/D ratio in between plasma samples and cancer tissues in ESCC patients showing high plasma C/D ratio; (3) Validation study of the clinical application of the plasma C/D ratio as a diagnostic and prognostic marker, by comparing with clinicopathologic factors in 96 ESCC patients. RESULTS: The plasma C/D ratio was significantly higher in the ESCC group than the controls (P=0.0134). A high plasma C/D ratio reflected the tumour C/D ratio, and significantly correlated with a poorer prognosis (P=0.0186). Moreover, the high C/D ratio was found to be an independent prognostic factor on multivariate analysis (P=0.0266; hazard ratio 5.988). CONCLUSION: Prediction of CCND1 amplification using plasma DNA is thought to be a promising prognostic biomarker in ESCC patients.
format Text
id pubmed-2865765
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-28657652011-04-27 Prediction of CCND1 amplification using plasma DNA as a prognostic marker in oesophageal squamous cell carcinoma Takeshita, H Ichikawa, D Komatsu, S Tsujiura, M Kosuga, T Deguchi, K Konishi, H Morimura, R Shiozaki, A Fujiwara, H Okamoto, K Otsuji, E Br J Cancer Molecular Diagnostics BACKGROUND: We aimed to develop a new biomarker to predict cyclin D1 (CCND1) status using plasma DNA in oesophageal squamous cell carcinoma (ESCC) patients. METHODS: We evaluated the ratio of the CCND1 (11q13) dosage to the dopamine receptor D2 (DRD2; 11q22-23) dosage (C/D ratio) as CCND1 copy number. This study was divided into three steps: (1) Determination of a cutoff value for the C/D ratio in test scale; (2) Comparison of the C/D ratio in between plasma samples and cancer tissues in ESCC patients showing high plasma C/D ratio; (3) Validation study of the clinical application of the plasma C/D ratio as a diagnostic and prognostic marker, by comparing with clinicopathologic factors in 96 ESCC patients. RESULTS: The plasma C/D ratio was significantly higher in the ESCC group than the controls (P=0.0134). A high plasma C/D ratio reflected the tumour C/D ratio, and significantly correlated with a poorer prognosis (P=0.0186). Moreover, the high C/D ratio was found to be an independent prognostic factor on multivariate analysis (P=0.0266; hazard ratio 5.988). CONCLUSION: Prediction of CCND1 amplification using plasma DNA is thought to be a promising prognostic biomarker in ESCC patients. Nature Publishing Group 2010-04-27 2010-04-13 /pmc/articles/PMC2865765/ /pubmed/20389301 http://dx.doi.org/10.1038/sj.bjc.6605657 Text en Copyright © 2010 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Molecular Diagnostics
Takeshita, H
Ichikawa, D
Komatsu, S
Tsujiura, M
Kosuga, T
Deguchi, K
Konishi, H
Morimura, R
Shiozaki, A
Fujiwara, H
Okamoto, K
Otsuji, E
Prediction of CCND1 amplification using plasma DNA as a prognostic marker in oesophageal squamous cell carcinoma
title Prediction of CCND1 amplification using plasma DNA as a prognostic marker in oesophageal squamous cell carcinoma
title_full Prediction of CCND1 amplification using plasma DNA as a prognostic marker in oesophageal squamous cell carcinoma
title_fullStr Prediction of CCND1 amplification using plasma DNA as a prognostic marker in oesophageal squamous cell carcinoma
title_full_unstemmed Prediction of CCND1 amplification using plasma DNA as a prognostic marker in oesophageal squamous cell carcinoma
title_short Prediction of CCND1 amplification using plasma DNA as a prognostic marker in oesophageal squamous cell carcinoma
title_sort prediction of ccnd1 amplification using plasma dna as a prognostic marker in oesophageal squamous cell carcinoma
topic Molecular Diagnostics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2865765/
https://www.ncbi.nlm.nih.gov/pubmed/20389301
http://dx.doi.org/10.1038/sj.bjc.6605657
work_keys_str_mv AT takeshitah predictionofccnd1amplificationusingplasmadnaasaprognosticmarkerinoesophagealsquamouscellcarcinoma
AT ichikawad predictionofccnd1amplificationusingplasmadnaasaprognosticmarkerinoesophagealsquamouscellcarcinoma
AT komatsus predictionofccnd1amplificationusingplasmadnaasaprognosticmarkerinoesophagealsquamouscellcarcinoma
AT tsujiuram predictionofccnd1amplificationusingplasmadnaasaprognosticmarkerinoesophagealsquamouscellcarcinoma
AT kosugat predictionofccnd1amplificationusingplasmadnaasaprognosticmarkerinoesophagealsquamouscellcarcinoma
AT deguchik predictionofccnd1amplificationusingplasmadnaasaprognosticmarkerinoesophagealsquamouscellcarcinoma
AT konishih predictionofccnd1amplificationusingplasmadnaasaprognosticmarkerinoesophagealsquamouscellcarcinoma
AT morimurar predictionofccnd1amplificationusingplasmadnaasaprognosticmarkerinoesophagealsquamouscellcarcinoma
AT shiozakia predictionofccnd1amplificationusingplasmadnaasaprognosticmarkerinoesophagealsquamouscellcarcinoma
AT fujiwarah predictionofccnd1amplificationusingplasmadnaasaprognosticmarkerinoesophagealsquamouscellcarcinoma
AT okamotok predictionofccnd1amplificationusingplasmadnaasaprognosticmarkerinoesophagealsquamouscellcarcinoma
AT otsujie predictionofccnd1amplificationusingplasmadnaasaprognosticmarkerinoesophagealsquamouscellcarcinoma

Ejemplares similares